Myriad Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Myriad Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$2.4M	Buy	15,400 +8,900	+137%	+$1.29M	0.33%	34
2021 Q4	$828K	Buy	+6,500	New	+$854K	0.09%	93

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Myriad Asset Management's JAZZ Position: Q1 2022 in Review

Myriad Asset Management increased its Jazz Pharmaceuticals (JAZZ) stake by 137% in Q1 2022, buying an estimated $1.29M and bringing the position to 15,400 shares worth $2.4M. The position accounts for 0.33% of the portfolio, ranked #34.

Myriad Asset Management first reported a position in JAZZ in Q4 2021 and has held it in 2 quarters since. 462 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

Myriad Asset Management held 15,400 shares of Jazz Pharmaceuticals worth $2.4M as of Q1 2022.
Myriad Asset Management bought 8,900 Jazz Pharmaceuticals shares in Q1 2022, an estimated $1.29M.
Jazz Pharmaceuticals made up 0.33% of Myriad Asset Management's portfolio in Q1 2022, its #34 holding.
Myriad Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
462 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on Myriad Asset Management's 13F filing for Q1 2022, filed 16 May 2022.